People · Operator
Named in public records as an officer, director or promoter · active 2017–2023 · Other Health Care, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Labconnect Holdings, Inc. | — | Other Health Care | Series B | $33.4M | $739.0M | 2017 |
| NeuBase Therapeutics, Inc. | — | Biotechnology | Series A | $17.1M | $42.7M | 2023 |
Eric Richman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Eric Richman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Anderson | 1 | 20 |
| Dov Goldstein | 1 | 6 |
| Dietrich Stephan | 1 | 4 |
| Jonathan Siegel | 1 | 4 |
| John Stobo | 1 | 3 |
| Ira Greenstein | 1 | 3 |
| Tim Johnson | 1 | 3 |
| Irach Taraporewala | 1 | 2 |
| June Almenoff | 1 | 2 |
| Thomas Riedhammer | 1 | 2 |
| Franklyn Prendergast | 1 | 2 |
| Andrew Limpert | 1 | 1 |
| Todd Branning | 1 | 1 |
| Sam Backenroth | 1 | 1 |
| Gerald McDougall | 1 | 1 |
| JEFF MAYHEW | 1 | 1 |
| ERIC HAYASHI | 1 | 1 |
| ALAIN CHETRIT | 1 | 1 |
| MYRON MURDOCK | 1 | 1 |
| Orin Hirschman | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.